RHR: The GLP-1 Blind Spot: What Ozempic Won’t Do for Your Metabolic Health

In this episode of Revolution Health Radio, Chris explores the science behind GLP-1 medications, including their powerful effects on appetite, weight loss, and cardiometabolic risk. He also uncovers the critical blind spots in the current conversation, including new research on long-term side effects, nutrient deficiencies, muscle loss, and the high rate of weight regain after discontinuation. You’ll learn why these drugs may be effective in the short term but fall short of addressing the root causes of obesity and metabolic dysfunction. Chris also explains who may benefit most from GLP-1 therapy and how to use these medications as part of a comprehensive strategy that includes nutrition, resistance training, and lifestyle interventions. The post RHR: The GLP-1 Blind Spot: What Ozempic Won’t Do for Your Metabolic Health appeared first on Chris Kresser.